Skip to main content

Allarity Therapeutics, Inc.

corporate_fare Company Profile

Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ALLR - Latest Insights

ALLR
Apr 28, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
ALLR
Apr 27, 2026, 7:44 AM EDT
Filing Type: 424B3
Importance Score:
7
ALLR
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
ALLR
Apr 10, 2026, 5:18 PM EDT
Filing Type: PRE 14A
Importance Score:
8
ALLR
Mar 30, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
9
ALLR
Mar 06, 2026, 8:22 AM EST
Filing Type: 8-K
Importance Score:
9
ALLR
Feb 19, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
ALLR
Feb 12, 2026, 4:18 PM EST
Filing Type: S-3
Importance Score:
7
ALLR
Feb 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
ALLR
Jan 29, 2026, 8:00 AM EST
Filing Type: 424B5
Importance Score:
8
ALLR
Jan 29, 2026, 7:49 AM EST
Filing Type: 8-K
Importance Score:
8